Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care
Orthopedic practice is moving away from a model that manages knee pain until the joint fails, to early structural intervention - a shift that raises the bar for what a cartilage repair product has to deliver. Regentis' GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage, with Phase II data showing approximately 100% greater KOOS improvement than microfracture at two years. With CE Mark approval in Europe, pivotal U.S. trial enrollment targeted for completion by approximately year end 2026, and platform work extending toward moderate osteoarthritis, the company is…